OK Biotech Co., Ltd.
TWSE:4155.TW
25.4 (TWD) • At close September 19, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) TWD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 1,191.985 | 1,483.523 | 1,263.378 | 1,484.413 | 1,241.252 | 1,120.346 | 1,233.076 | 1,040.462 | 856.551 | 633.765 | 1,074.281 | 656.695 | 502.536 | 405.99 | 280.794 |
| Cost of Revenue
| 987.674 | 1,138.565 | 1,076.552 | 1,158.458 | 945.127 | 818.237 | 945.023 | 829.889 | 579.659 | 467.334 | 783.357 | 463.015 | 367.522 | 309.224 | 183.07 |
| Gross Profit
| 204.311 | 344.958 | 186.826 | 325.955 | 296.125 | 302.109 | 288.053 | 210.573 | 276.892 | 166.431 | 290.924 | 193.68 | 135.014 | 96.766 | 97.724 |
| Gross Profit Ratio
| 0.171 | 0.233 | 0.148 | 0.22 | 0.239 | 0.27 | 0.234 | 0.202 | 0.323 | 0.263 | 0.271 | 0.295 | 0.269 | 0.238 | 0.348 |
| Reseach & Development Expenses
| 46.713 | 48.731 | 28.736 | 45.461 | 32.563 | 40.79 | 32.6 | 20.18 | 19.947 | 22.896 | 22.845 | 19.086 | 15.306 | 12.482 | 12.311 |
| General & Administrative Expenses
| 73.939 | 68.53 | 62.668 | 72.137 | 76.112 | 70.277 | 68.24 | 58.011 | 73.152 | 75.504 | 48.85 | 35.123 | 24.066 | 17.927 | 13.76 |
| Selling & Marketing Expenses
| 74.467 | 87.56 | 85.573 | 80.004 | 80.419 | 56.961 | 49.897 | 30.311 | 75.061 | 41.145 | 33.608 | 29.249 | 20.551 | 18.424 | 8.834 |
| SG&A
| 148.406 | 156.09 | 148.241 | 152.141 | 156.531 | 127.238 | 118.137 | 88.322 | 148.213 | 116.649 | 82.458 | 64.372 | 44.617 | 36.351 | 22.594 |
| Other Expenses
| -216.373 | 60.892 | 13.845 | -8.07 | -1.946 | 34.299 | -8.272 | 0.346 | 11.277 | 19.096 | 13.585 | 2.625 | 3.174 | 4.587 | 0.611 |
| Operating Expenses
| 216.373 | 204.821 | 176.977 | 189.532 | 187.148 | 160.386 | 157.474 | 102.569 | 163.643 | 127.975 | 149.833 | 83.458 | 59.923 | 48.833 | 34.905 |
| Operating Income
| -12.062 | 211.624 | 49.312 | 170.099 | 147.474 | 141.723 | 130.579 | 108.004 | 113.249 | 38.456 | 141.091 | 110.222 | 75.091 | 47.933 | 62.819 |
| Operating Income Ratio
| -0.01 | 0.143 | 0.039 | 0.115 | 0.119 | 0.126 | 0.106 | 0.104 | 0.132 | 0.061 | 0.131 | 0.168 | 0.149 | 0.118 | 0.224 |
| Total Other Income Expenses Net
| 20.088 | -36.03 | -3.172 | -18.443 | -4.096 | 59.872 | 32.615 | 24.574 | 30.751 | 40.621 | 14.748 | -3.215 | 4.869 | -6.367 | -0.664 |
| Income Before Tax
| 8.026 | 175.594 | 46.14 | 151.656 | 143.378 | 201.595 | 163.194 | 132.578 | 144 | 79.077 | 155.839 | 107.007 | 79.96 | 41.566 | 62.155 |
| Income Before Tax Ratio
| 0.007 | 0.118 | 0.037 | 0.102 | 0.116 | 0.18 | 0.132 | 0.127 | 0.168 | 0.125 | 0.145 | 0.163 | 0.159 | 0.102 | 0.221 |
| Income Tax Expense
| 9.62 | 38.868 | 14.718 | 30.353 | 30.695 | 41.084 | 36.385 | 47.377 | 33.031 | 7.713 | 17.634 | 10.329 | 7.62 | 3.83 | 12.455 |
| Net Income
| -1.594 | 143.462 | 31.422 | 129.728 | 125.76 | 161.362 | 126.809 | 85.201 | 110.969 | 71.364 | 138.205 | 96.678 | 72.34 | 37.736 | 49.7 |
| Net Income Ratio
| -0.001 | 0.097 | 0.025 | 0.087 | 0.101 | 0.144 | 0.103 | 0.082 | 0.13 | 0.113 | 0.129 | 0.147 | 0.144 | 0.093 | 0.177 |
| EPS
| -0.012 | 1.34 | 0.3 | 1.39 | 1.49 | 2.04 | 1.88 | 1.29 | 1.68 | 1.11 | 2.82 | 2.14 | 2.02 | 1.02 | 2 |
| EPS Diluted
| -0.012 | 1.14 | 0.26 | 1.3 | 1.42 | 2.04 | 1.82 | 1.25 | 1.64 | 1.1 | 2.74 | 2.06 | 1.96 | 1.01 | 1.93 |
| EBITDA
| 100.104 | 279.506 | 105.194 | 220.176 | 189.028 | 241.801 | 190.64 | 161.699 | 179.722 | 117.195 | 183.517 | 119.238 | 90.575 | 48.171 | 64.846 |
| EBITDA Ratio
| 0.084 | 0.188 | 0.083 | 0.148 | 0.152 | 0.216 | 0.155 | 0.155 | 0.21 | 0.185 | 0.171 | 0.182 | 0.18 | 0.119 | 0.231 |